Tolvaptan: the evidence for its therapeutic value in acute heart failure syndrome.

However, during the last scheduled assessment at study end, three out of the 10 study domains (quality of life, social limitation, and overall summary score) showed statistically significant changes favoring tolvaptan; the remaining domains also favored tolvaptan numerically but did not reach statistical significance ( Konstam et al. 2007 ).

also in 111,027 other papers